Trial Profile

Does using fidaxomicin to treat Clostridium difficile infection (CDI) reduce the recovery of C. difficile from faeces, patient's skin and the immediate environment compared to treatment with vancomycin or metronidazole?

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 13 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

08 Sep 2021 Status changed from active, no longer recruiting to completed.
16 Apr 2019 Results assessing efficacy of Fidaxomicin in patients with Clostridium difficile infections, presented at the 29th European Congress of Clinical Microbiology and Infectious Diseases
03 Dec 2015 Accrual to date is 116% according to United Kingdom Clinical Research Network.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com